CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Celebrate National Blood Donor Month throughout January by inviting eligible individuals to donate b...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
As communicated on January 21, 2020, CTS will implement the licensed Grifols Babesia test for sample...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...